Clinical Trials Directory

Trials / Terminated

TerminatedNCT02317042

Juno Perth Clinical Trial

The Evaluation of the Sleep-Breathing Treatment Algorithm: AutoEPAP iVAPS

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
25 (actual)
Sponsor
ResMed · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study is to evaluate the efficacy of a new therapy (Automatic Expiratory Positive Airway Pressure with intelligent Volume Assured Pressure Support (AutoEPAP iVAPS)) designed to treat respiratory insufficiency, respiratory failure and/or nocturnal hypoventilation with upper airway obstruction. The study will be performed in two phases: In a sleep unit and in the home environment. The new therapy will be compared against two existing ventilator therapies: "Spontaneous Timed (ST) mode" and "Intelligent Volume Assured Pressure Support (iVAPS)".

Detailed description

Phase I: AutoEPAP iVAPS will be compared against two existing ventilator therapies: "Spontaneous Timed (ST) mode" and "Intelligent Volume Assured Pressure Support (Fixed EPAP iVAPS)" in current NIV users with respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD),Obesity Hypoventilation Syndrome (OHS) or Neuromuscular Disease (NMD). Patients will spend a total of 3 nights in the sleep laboratory in the three modes described above. The apnoea-hypopnoea index will be the primary outcome measure. Phase II: AutoEPAP iVAPS will be compared to ST mode over a period of 7 nights in the patients' home. The mean EPAP setting of each device will be the primary outcome measure.

Conditions

Interventions

TypeNameDescription
DEVICEJunoJuno device set to ST mode with participant's current therapy settings.
DEVICEJunoJuno device set to AutoEPAP iVAPS mode.
DEVICEJunoJuno device set to Fixed EPAP iVAPS mode.

Timeline

Start date
2015-05-29
Primary completion
2015-11-01
Completion
2015-11-29
First posted
2014-12-15
Last updated
2021-06-08
Results posted
2021-06-08

Locations

2 sites across 1 country: Australia

Source: ClinicalTrials.gov record NCT02317042. Inclusion in this directory is not an endorsement.